First-Line MET Tyrosine Kinase Inhibitors versus Immunotherapy ± Chemotherapy for Patients with MET Exon 14 Skipping Mutant Metastatic NSCLC
Contributors
Pecci, FedericaPublished in
Clinical cancer research, vol. 31, no. 22, p. 4802-4813Publication date
2025-11-14Abstract
Keywords
- Humans
- Carcinoma, Non-Small-Cell Lung / drug therapy
- Carcinoma, Non-Small-Cell Lung / genetics
- Carcinoma, Non-Small-Cell Lung / pathology
- Carcinoma, Non-Small-Cell Lung / mortality
- Proto-Oncogene Proteins c-met / genetics
- Proto-Oncogene Proteins c-met / antagonists & inhibitors
- Male
- Protein Kinase Inhibitors / therapeutic use
- Protein Kinase Inhibitors / administration & dosage
- Female
- Lung Neoplasms / drug therapy
- Lung Neoplasms / genetics
- Lung Neoplasms / pathology
- Lung Neoplasms / mortality
- Middle Aged
- Aged
- Mutation
- Exons / genetics
- Antineoplastic Combined Chemotherapy Protocols / therapeutic use
- Antineoplastic Combined Chemotherapy Protocols / adverse effects
- Immune Checkpoint Inhibitors / administration & dosage
- Immune Checkpoint Inhibitors / therapeutic use
- Adult
- Aged, 80 and over
- Neoplasm Metastasis
- Tyrosine Kinase Inhibitors
UNIGE affiliation entities
Funding
- NCI NIH HHS [K99 CA297010]
- National Cancer Institute (NCI) [NIH NCI 1K99CA297010]
Citation (ISO format)
PECCI, Federica et al. First-Line MET Tyrosine Kinase Inhibitors versus Immunotherapy ± Chemotherapy for Patients with MET Exon 14 Skipping Mutant Metastatic NSCLC. In: Clinical cancer research, 2025, vol. 31, n° 22, p. 4802–4813. doi: 10.1158/1078-0432.CCR-25-1735
Main files (1)
Article (Published version)
Secondary files (3)
Appendix
Appendix
Appendix
Identifiers
- PID : unige:192252
- DOI : 10.1158/1078-0432.CCR-25-1735
- PMID : 40864503
- PMCID : PMC12616240
